Advertisement
Advertisement
October 22, 2025
Antithrombogenic Indication Cleared for Access Vascular’s HydroMid and HydroPICC
October 22, 2025—Access Vascular, Inc. announced that the FDA cleared a new indication for its single-lumen Mimix HydroMid midline catheter and its single- and dual-lumen HydroPICC peripherally inserted central catheter.
According to the company, the updated labeling recognizes the devices’ hydrogel material as having antithrombogenic properties designed to reduce the risk of thrombus formation on catheter surfaces.
Access Vascular stated that its Mimix technology is a bulk hydrogel material that creates a steric, molecular-level barrier on both the external surfaces and internal fluid pathways of the catheter.
In vitro studies demonstrated that this barrier reduces thrombus accumulation and occlusion; however, its clinical impact in human trials has not yet been evaluated, and the devices are not intended for the treatment of existing vein thrombosis, advised the company.
Advertisement
Advertisement
